RITTER PHARMACEUTICALS INC Uncategorized Contracts & Agreements
27 Contracts & Agreements
- Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes (Filed With SEC on May 2, 2023)
- Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes (Filed With SEC on May 2, 2023)
- Letter to Michael P. Poirier, dated January 13, 2023, regarding compensatory changes (Filed With SEC on May 2, 2023)
- Amendment to Technology Transfer Agreement between Yi Xin Zhen Duan Jishu (Suzhou) Ltd. and Qualigen, Inc., dated August 5, 2021 (Filed With SEC on November 15, 2021)
- Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021 (Filed With SEC on August 16, 2021)
- Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated March 1, 2021 (Filed With SEC on May 14, 2021)
- Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021 (Filed With SEC on May 14, 2021)
- Technology Transfer Agreement dated as of October 7, 2020 between Qualigen, Inc. and Yi Xin Zhen Duan Jishu (Suzhou) Ltd (Filed With SEC on October 9, 2020)
- Letter agreement (for payment date extension) between the Company and Sekisui Diagnostics, LLC dated June 23, 2020 (Filed With SEC on August 14, 2020)
- Form of Lock-Up Agreement (Filed With SEC on May 29, 2020)
- Contingent Value Rights Agreement, dated May 22, 2020, by and among the Company, John Beck in the capacity of CVR Holders Representative and Andrew J. Ritter in his capacity as a... (Filed With SEC on May 29, 2020)
- Form of CVR Agreement, by and among Ritter Pharmaceuticals, Inc., Andrew Ritter, in his capacity as the initial CVR Holders Representative, and Andrew Ritter, in his capacity as a... (Filed With SEC on January 21, 2020)
- Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter dated October 15, 2019 (Filed With SEC on October 15, 2019)
- Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and John W. Beck, dated October 15, 2019 (Filed With SEC on October 15, 2019)
- Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter, dated October 15, 2019 (Filed With SEC on October 15, 2019)
- Amended and Restated Offer Letter, dated June 26, 2018, by and between Ritter Pharmaceuticals, Inc and Andrew J. Ritter (Filed With SEC on August 14, 2018)
- Offer Letter with John W. Beck, dated May 23, 2018 (Filed With SEC on May 29, 2018)
- RITTERPHARMACEUTICALS, INC. WARRANTAGENCY AGREEMENT (Filed With SEC on September 28, 2017)
- RITTERPHARMACEUTICALS, INC. WARRANTAGENCY AGREEMENT (Filed With SEC on July 18, 2017)
- UNDERWRITINGAGREEMENT between RITTERPHARMACEUTICALS, INC. and AEGISCAPITAL CORP., asRepresentative of the Several Underwriters (Filed With SEC on July 18, 2017)
- SECOND AMENDMENT TO 2015 EQUITY INCENTIVEPLAN (Effective June 2, 2017) (Filed With SEC on June 6, 2017)
- UNDERWRITINGAGREEMENT between RITTERPHARMACEUTICALS, INC. and AEGISCAPITAL CORP., asRepresentative of the Several Underwriters (Filed With SEC on October 27, 2016)
- MASTERSERVICE AGREEMENT (Filed With SEC on December 31, 2015)
- RITTERPHARMACEUTICALS, INC. AMENDMENTNo. 4 TO AMENDED AND RESTATED INVESTORS’ RIGHTSAGREEMENT (Filed With SEC on December 31, 2015)
- LETTER OFAGREEMENT Date: October 20, 2015 (Filed With SEC on November 10, 2015)
- PUT AND CALL OPTION AGREEMENT (Filed With SEC on March 23, 2015)
- Exhibit A (Filed With SEC on March 23, 2015)
